These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29313971)

  • 21. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.
    Lustgarten J; Dominguez AL; Cuadros C
    Eur J Immunol; 2004 Mar; 34(3):752-761. PubMed ID: 14991605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
    Ohlén C; Kalos M; Hong DJ; Shur AC; Greenberg PD
    J Immunol; 2001 Feb; 166(4):2863-70. PubMed ID: 11160355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T Cells: A CD4-dependent mechanism.
    Humphreys IR; Loewendorf A; de Trez C; Schneider K; Benedict CA; Munks MW; Ware CF; Croft M
    J Immunol; 2007 Aug; 179(4):2195-202. PubMed ID: 17675479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic Activity and Memory T Cell Subset Distribution of
    Kuznetsova M; Lopatnikova J; Shevchenko J; Silkov A; Maksyutov A; Sennikov S
    Front Immunol; 2019; 10():1017. PubMed ID: 31143180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation.
    Muraoka D; Seo N; Hayashi T; Hyuga-Amaike C; Okamori K; Tawara I; Harada N; Shiku H
    Oncotarget; 2017 May; 8(19):30766-30780. PubMed ID: 28430604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.
    Song A; Song J; Tang X; Croft M
    Eur J Immunol; 2007 May; 37(5):1224-32. PubMed ID: 17429847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones.
    Rohrer JW; Barsoum AL; Coggin JH
    J Immunol; 2006 Mar; 176(5):2844-56. PubMed ID: 16493041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
    Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
    J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.
    Hombach AA; Chmielewski M; Rappl G; Abken H
    Hum Gene Ther; 2013 Mar; 24(3):259-69. PubMed ID: 23350854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
    Amani MF; Rolig AS; Redmond WL
    J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.